Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer's disease
AssigneeUniversity of South Florida
InventorChuanhai Cao
Life of this patent
Estimating the term…
Abstract
Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aβ protein levels; (ii) reduce Aβ aggregation: (iii) maintain AβPP protein levels; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK-3β protein; (vi) decrease GSK-3β protein levels; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein levels, in said patient without severe psychological impairments and side effects associated with higher doses of THC.
Claims14
A method for reducing β-amyloid (Aβ) expression in Alzheimer's patients comprising administering tetrahydrocannabinol (THC) and melatonin to a patient suffering from Alzheimer's disease, wherein the THC is administered in an ultra-low dose amount of from about 0.2 μg/kg to about 0.02 mg/kg of body weight of the patient and melatonin is administered in an amount from about 0.11 mg/kg to about 1.1 mg/kg of body weight of the patient without psychological impairments and side effects associated with higher doses of THC.
A method for reducing amyloid β (Aβ) aggregation in Alzheimer's patients comprising administering tetrahydrocannabinol (THC) and melatonin to a patient suffering from Alzheimer's disease wherein THC is administered in an ultra-low dose amount of from about 0.2 μg/kg to about 0.02 mg/kg of body weight of the patient and melatonin is administered in an amount from about 0.11 mg/kg to about 1.1 mg/kg of body weight of the patient without psychological impairments and side effects associated with higher doses of THC.
A method for maintaining amyloid β precursor protein (AβPP) expression levels in Alzheimer's patients comprising administering tetrahydrocannabinol (THC) and melatonin to a patient suffering from Alzheimer's disease wherein THC is administered in an ultra-low dose amount of from about 0.2 μg/kg to about 0.02 mg/kg of body weight of the patient and melatonin is administered in an amount from about 0.11 mg/kg to about 1.1 mg/kg of body weight of the patient without psychological impairments and side effects associated with higher doses of THC.
A method for enhancing mitochondrial functioning in Alzheimer's patients comprising administering tetrahydrocannabinol (THC) and melatonin to a patient suffering from Alzheimer's disease wherein THC is administered in an ultra-low dose amount of from about 0.2 μg/kg to about 0.02 mg/kg of body weight of the patient and melatonin is administered in an amount from about 0.11 mg/kg to about 1.1 mg/kg of body weight of the patient without psychological impairments and side effects associated with higher doses of THC.
A method for decreasing the phosphorylation of glycogen synthase kinase-3β (GSK-3β) protein in Alzheimer's patients comprising administering tetrahydrocannabinol (THC) and melatonin to a patient suffering from Alzheimer's disease wherein THC is administered in an ultra-low dose amount of from about 0.2 μg/kg to about 0.02 mg/kg of body weight of the patient and melatonin is administered in an amount from about 0.11 mg/kg to about 1.1 mg/kg of body weight of the patient without psychological impairments and side effects associated with higher doses of THC.
A method for maintaining Tau protein expression in an Alzheimer's patient comprising administering tetrahydrocannabinol (THC) and melatonin to a patient suffering from Alzheimer's disease wherein THC is administered in an ultra-low dose amount of from about 0.2 μg/kg to about 0.02 mg/kg of body weight of the patient and melatonin is administered in an amount from about 0.11 mg/kg to about 1.1 mg/kg of body weight of the patient without psychological impairments and side effects associated with higher doses of THC.
A method for decreasing glycogen synthase kinase-3β (GSK-3β) protein levels in Alzheimer's patients comprising administering tetrahydrocannabinol (THC) and melatonin to a patient suffering from Alzheimer's disease, wherein the THC is administered in an ultra-low dose amount per 70 kg patient of from about 0.2 μg/kg to about 0.02 mg/kg of body weight of the patient and melatonin is administered in an amount from about 0.11 mg/kg to about 1.1 mg/kg of body weight of the patient without psychological impairments and side effects associated with higher doses of THC.
Dependencies are inferred from the claim text.